Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call
Generado por agente de IAAinvest Technical Radar
martes, 29 de octubre de 2024, 4:10 pm ET1 min de lectura
BTMD--
Biote, a leading provider of personalized hormone optimization and therapeutic wellness solutions, has announced the release of its third quarter 2024 financial results and a subsequent conference call. The company, which specializes in preventive health care, will unveil its financial performance for the quarter on Tuesday, November 12, 2024, after market close.
The conference call, scheduled for the same day at 5:00 p.m. ET, will provide an opportunity for investors and stakeholders to discuss the firm's results with Biote's management team. Participants can join via U.S toll-free number (844) 481-2820 or International number (412) 317-0679. A webcast replay will be available on the company's Investor Relations website after the event.
Biote's financial performance in recent quarters has been marked by steady revenue growth and improved profitability. In the third quarter of 2023, the company reported an 8.5% increase in revenue, driven by procedure revenue growth of 7.4% and dietary supplement revenue growth of 5.1%. Gross profit margin improved to 68.9%, a 70-basis point increase from the prior year period. Net income soared to $19.6 million, representing a net income margin of 43.1%, compared to a net income margin of 1.2% in the prior year period.
Biote's success can be attributed to several factors, including effective cost management strategies, investment in capabilities and geographic reach, and the expansion of its wellness offerings. The company's commitment to driving profitable growth through consistent strategy execution has positioned it well for continued success in the coming quarters.
As the preventive health market evolves, Biote remains well-positioned for continued profitable growth, thanks to its leading presence, unparalleled operating experience, and evidence-backed protocols that promote patient health and well-being. The company's financial performance compares favorably to its competitors in the preventive health care industry, reflecting its strong business model and commitment to innovation.
The conference call, scheduled for the same day at 5:00 p.m. ET, will provide an opportunity for investors and stakeholders to discuss the firm's results with Biote's management team. Participants can join via U.S toll-free number (844) 481-2820 or International number (412) 317-0679. A webcast replay will be available on the company's Investor Relations website after the event.
Biote's financial performance in recent quarters has been marked by steady revenue growth and improved profitability. In the third quarter of 2023, the company reported an 8.5% increase in revenue, driven by procedure revenue growth of 7.4% and dietary supplement revenue growth of 5.1%. Gross profit margin improved to 68.9%, a 70-basis point increase from the prior year period. Net income soared to $19.6 million, representing a net income margin of 43.1%, compared to a net income margin of 1.2% in the prior year period.
Biote's success can be attributed to several factors, including effective cost management strategies, investment in capabilities and geographic reach, and the expansion of its wellness offerings. The company's commitment to driving profitable growth through consistent strategy execution has positioned it well for continued success in the coming quarters.
As the preventive health market evolves, Biote remains well-positioned for continued profitable growth, thanks to its leading presence, unparalleled operating experience, and evidence-backed protocols that promote patient health and well-being. The company's financial performance compares favorably to its competitors in the preventive health care industry, reflecting its strong business model and commitment to innovation.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios